CORDIS
EU research results

CORDIS

English EN
Ultra-high resolution and ultra-sensitive fluorescence methods for objective sub-cellular diagnosis of early disease and disease progression in breast and prostate cancer

Ultra-high resolution and ultra-sensitive fluorescence methods for objective sub-cellular diagnosis of early disease and disease progression in breast and prostate cancer

Objective

The overall objective of this proposal is to develop and validate a quantitative, minimally invasive diagnostic tool for early and conclusive detection, diagnosis and monitoring of disease and disease progression of breast and prostate cancer. A methodology will be developed making use of a combination of the probably most exciting recent advances in the field of light microscopy, for fluorescence-based optical imaging of individual sample cells. It includes advances which will take the spatial resolution far beyond the fundamental limits of optical resolution, the sensitivity down to an ultimate single-molecule level, and multi-parameter detection schemes significantly increasing the fluorescence information by which these cellular images can be analysed. Apart from detecting and identifying tumour markers in the samples, tumour-specific spatio-temporal molecular distributions within the intact sample cells will be exploited. This is to date an almost unexploited dimension of diagnostic information. By combining and supporting these novel optical methods with state-of-the-art affinity molecule biotechnology, , tumor biomarkers, fluorophore chemistry, and bioinformatic validation tools, all possible means will be exploited to extract a maximum amount of information out of very small amounts of sample material. We thereby expect that an improved, early and reliable diagnosis of breast and prostate cancer will be possible, from amounts of sample material small enough that a minimally invasive procedure such as Fine-needle aspiration (FNA) can be used. In addition, by the minimally invasive FNA-based sampling, serious sampling-related side-effects, such as seeding and spread of cancer cells can be completely avoided. Given the high incidence of breast and prostate cancer, and the utmost importance of an early and conclusive diagnosis for the prognosis of these diseases, the relevance of this project can not be overestimated.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

KUNGLIGA TEKNISKA HOEGSKOLAN

Address

Brinellvagen 8
100 44 Stockholm

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 101 193

Administrative Contact

Monica Thorén (Ms.)

Participants (11)

Sort alphabetically

Sort by EU Contribution

Expand all

NEODYNAMICS AB

Sweden

EU Contribution

€ 265 430

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 333 963

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 351 116

HEINRICH-HEINE-UNIVERSITAET DUESSELDORF

Germany

EU Contribution

€ 451 958

SENSL TECHNOLOGIES LIMITED

Ireland

EU Contribution

€ 361 557

BECKER & HICKL GMBH

Germany

EU Contribution

€ 285 314

UNIVERSITAT ZU LUBECK

Germany

EU Contribution

€ 270 192

UNIVERSITAET SIEGEN

Germany

EU Contribution

€ 177 112

TURUN YLIOPISTO

Finland

EU Contribution

€ 210 326

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 128 604

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 261 009

Project information

Grant agreement ID: 201837

Status

Closed project

  • Start date

    1 June 2008

  • End date

    31 May 2012

Funded under:

FP7-HEALTH

  • Overall budget:

    € 5 542 587,20

  • EU contribution

    € 4 197 774

Coordinated by:

KUNGLIGA TEKNISKA HOEGSKOLAN

Sweden